KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Preferred Stock Liabilities (2017 - 2018)

Twist Bioscience has reported Preferred Stock Liabilities over the past 2 years, most recently at $290.5 million for Q3 2018.

  • Quarterly Preferred Stock Liabilities changed N/A to $290.5 million in Q3 2018 from the year-ago period, while the trailing twelve-month figure was $290.5 million through Sep 2018, changed N/A year-over-year, with the annual reading at $290.5 million for FY2018, 690.95% up from the prior year.
  • Preferred Stock Liabilities was $290.5 million for Q3 2018 at Twist Bioscience, up from $25.9 million in the prior quarter.
  • Over five years, Preferred Stock Liabilities peaked at $290.5 million in Q3 2018 and troughed at $9.1 million in Q4 2017.